

Chloroquine and Hydroxychloroquine for the treatment of COVID-19: A Systematic Review and Meta-analysis

Arunmozhimaran Elavarasi, MD¹, Manya Prasad, MD², Tulika Seth, MD³, Ranjit Kumar Sahoo, MD⁴, Karan Madan, MD⁵, Neeraj Nischal, MD⁶, Manish Soneja, MD⁶, Atul Sharma, MD⁴, Subir Kumar Maulik, MD⁷, Shalimar, MD^{8*}, Pramod Garg, MD^{8*}

¹Departments of Neurology, ³Clinical Hematology, ⁴Medical Oncology, ⁵Pulmonary Medicine, Critical care and Sleep Disorders; ⁶Medicine, ⁷Pharmacology, and ⁷Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences, New Delhi 110029, India.

²Department of Community Medicine, NDMC Medical College, New Delhi.

*Corresponding Authors

Dr. Shalimar, MD

Professor of Gastroenterology,

All India Institute of Medical Sciences,

New Delhi, India

Email: drshalimar@yahoo.com

or

Dr. Pramod Garg, MD

Professor of Gastroenterology,

All India Institute of Medical Sciences,

New Delhi, India

Email: pkgarg@aiims.ac.in

Running title: Chloroquine/HCQ for treating COVID-19

Abstract

Background: There is no effective therapy for COVID-19. Hydroxychloroquine (HCQ) and chloroquine (CQ) have been used for its treatment but their safety and efficacy remain uncertain.

Objective: We performed a systematic review to synthesize the available data on the efficacy and safety of CQ and HCQ for the treatment of COVID-19.

Methods: Two reviewers searched for published and pre-published relevant articles between December 2019 to 8th June 2020. The data from the selected studies were abstracted and analyzed for efficacy and safety outcomes. Critical appraisal of the evidence was done by Cochrane risk of bias tool and Newcastle Ottawa scale. The quality of evidence was graded as per the GRADE approach.

Results: We reviewed 12 observational and 3 randomized trials which included 10659 patients of whom 5713 received CQ/HCQ and 4966 received only standard of care. The efficacy of CQ/HCQ for COVID-19 was inconsistent across the studies. Meta-analysis of included studies revealed no significant reduction in mortality with HCQ use [RR 0.98 95% CI 0.66-1.46], time to fever resolution [mean difference -0.54 days (-1.19-0.11)] or clinical deterioration/development of ARDS with HCQ [RR 0.90 95% CI 0.47-1.71]. There was a higher risk of ECG abnormalities/arrhythmia with HCQ/CQ [RR 1.46 95% CI 1.04 to 2.06]. The quality of evidence was graded as very low for these outcomes.

Author's Conclusion: The available evidence suggests that CQ or HCQ does not improve clinical outcomes in COVID-19. Well-designed randomized trials are required for assessing the efficacy and safety of HCQ and CQ for COVID-19..

Keywords: Chloroquine; Hydroxychloroquine; COVID-19; SARS-CoV-2; Meta-analysis

Background

A novel coronavirus- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease 2019 (COVID-19). World Health Organization (WHO) declared COVID-19 as a global pandemic on 11th March 2020. As of 8th June, more than 7.1 million people have been infected, and 406959 have died due to COVID-19.[1] In the absence of any definitive therapy, repurposing of some commonly used antivirals and immunomodulatory drugs has been tried to treat COVID-19. Among such drugs, hydroxychloroquine (HCQ) was one of the first drugs to be tested for COVID-19 and has been recommended in national treatment guidelines in some countries such as India and the US [2]. Although the US FDA has not approved the drug for its clinical use, CDC (USA) has mentioned its use on the website as an approved drug lending support to such claims.[3] Clinical studies evaluating the efficacy of HCQ, have several limitations such as small sample size, heterogeneity, inconsistent results and early stoppage of trials and thus robust data are lacking with regard to its efficacy and safety. In view of the recent controversy, public anxiety and lack of effective therapy, it is therefore important to systematically review the literature, critically appraise it and present credible evidence, which might help treating clinicians, policy makers and patients make informed decisions.

We performed a systematic review of studies that tested the efficacy of chloroquine (CQ) and HCQ for the SARS-CoV-2 infection/COVID-19 and did a meta-analysis of the relevant studies.

Objective:

This systematic review was carried out to answer the following research question:

In patients with COVID-19, is the use of CQ or HCQ effective and safe in reducing mortality and improving the clinical course, fever remission and virologic clearance as compared to no CQ/HCQ?

Methods:

Criteria for considering relevant studies for this review were as follows

1. Types of studies:

We included studies on humans, which were randomized controlled trials (RCTs), prospective or retrospective case series or cohort studies with a control arm. We excluded case series without a control arm, case reports, review articles, viewpoints, experimental in vitro studies, editorials, and expert opinion. We included indexed studies from PubMed, Google scholar as well as non-indexed and pre-print articles from various pre-print servers because the latest information on COVID-19, a new disease, available on these pre-print servers might be valuable for the present review.

2. Types of Participants

We included human studies in which patients with confirmed COVID-19 of all ages and sexes were enrolled.

3. Types of Interventions

We sought studies in which patients were given HCQ or CQ in any dose, alone or combined with other drugs and had compared with patients in whom HCQ or chloroquine was not given.

4. Outcomes

For each study, we sought the following outcomes:

(i) Efficacy outcomes

- **Clinical outcomes:** mortality, improvement in clinical course in terms of time to fever resolution, and development of acute respiratory distress syndrome (ARDS) or need for mechanical ventilation suggestive of worsening of disease.
 - **Radiologic outcomes:** Improvement in findings on CT chest
 - **Laboratory outcomes:** Virologic clearance as determined by RT-PCR test
- (ii) **Safety outcomes:** Adverse effects associated with HCQ/Chloroquine

Search strategy and Identification of studies:

Two authors independently searched the PubMed, Google Scholar and MedRxiv databases using the following search terms: “[(chloroquine OR hydroxychloroquine) AND (COVID-19 OR SARS-CoV-2)]” from 2000 to 8th June 2020. Studies of all languages were included. No limits were applied to the search results except studies in humans. Hand searching of cross-references of original articles, reviews and pre-published articles was also performed to find additional relevant articles.

Data collection and analysis

The citations were retrieved into a reference management software (Zotero version 5.0.85). Duplicate citations were removed. All the remaining studies were reviewed by going through their title and abstract to select the studies meeting our inclusion criteria mentioned above. Data on outcomes were extracted by one reviewer (AE) and cross-checked by another reviewer (Sh). The risk of bias was assessed using the Cochrane Risk of Bias Tool for RCTs[4] and the Newcastle Ottawa Scale for Cohort studies.[5] Meta-analysis of RCTs was done for the outcomes virologic clearance and time to fever resolution. Meta-analyses of the other studies were done for the following outcomes:

1. Mortality,
2. Worsening of clinical condition in the form of development of ARDS or need for mechanical ventilation,
3. Virologic clearance
4. ECG abnormalities and de novo ventricular arrhythmias.

We calculated relative treatment effects using Mantel-Haenszel random-effects model, expressed as RRs with 95% (CIs) for the outcomes: mortality, worsening of pneumonia/ARDS/mechanical ventilation, and virologic clearance. For the outcome ECG abnormalities/de novo ventricular arrhythmia, odds ratio(OR) with 95% CI was calculated using the generic inverse variance method. Adjusted odds ratio was used whenever available and unadjusted odds ratio in other circumstances. The standard error was calculated from the 95% confidence intervals. In the case of continuous variables, the mean difference for each study was plotted, and the summary statistic was calculated using the inverse variance method. All the analyses were performed using RevMan 5.3.

The certainty in the evidence was graded using the GRADE methodology (Grading of Recommendations, Assessment, Development and Evaluations).[6]

Results:

Description of studies

The PubMed search yielded 579 articles. MedRxiv search yielded 291 articles and Google scholar search yielded 1360 articles. The Cohen's Kappa for inter-rater agreement between the 2 reviewers was 0.8. Hand searching of relevant articles yielded one article. After excluding articles that did not fulfill the inclusion criteria and duplicate citations, we had 20 articles to be

examined in detail.

Out of these 20, one study was excluded as it compared two doses of HCQ, the comparison was with historical data, and complete information was missing.[7] Another article was excluded as it had incomplete outcome data.[8] Two studies were excluded as the authors had withdrawn the papers.[9,10] Another study was excluded as the exposure data and co-interventions were incompletely reported.[11] Thus, 15 articles [12–26] were included for the final review and synthesis of evidence, and assessment of the risk of bias. PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) flow chart has been provided (Figure 1)

Studies included

The 15 studies that were selected had included 10659 patients. Of these, 12 were cohort studies which had a control group and 3 RCTs. The details about the study design, participants, interventions and outcomes are described in Tables 1-3.

Risk of Bias in included studies

Assessment of bias for the 3 RCTs and 12 cohort studies revealed a significant risk of bias as assessed against various quality parameters. Most of the comparative studies were of poor methodologic quality and were subject to high risk of bias owing to the non-randomized study design and the lack of placebo control. Even the RCTs were unblinded and subject to risk of assessment bias. The details are shown in Figure 2 and Table 4.

Effects of CQ and HCQ on COVID-19:

Of the 15 studies, 2 studies reported the use of CQ and 13 reported the use of HCQ. Of the total

10659 patients included in 15 studies, 5713 received CQ or HCQ along with standard of care and 4946 received only standard of care (no CQ/HCQ). Each study reported only a few of the outcomes of interest.

Efficacy Outcomes:

Mortality: 7 cohort studies reported mortality. Two of them showed a reduction in mortality, 3 did not show any benefit and 2 showed higher mortality with the use of HCQ compared to controls (Table 1). However on after adjusting for baseline severity and comorbidities, one of the cohort studies did not show any difference in mortality with the use of HCQ.[21]

Clinical Course: One RCT and 5 cohort studies reported the effect of CQ/HCQ on the clinical course of the disease with either improvement or worsening in the form of development of ARDS or requirement for mechanical ventilation. One cohort study reported higher disease progression, one RCT and 4 cohort studies showed no difference in clinical course between CQ/HCQ and standard of care arm.

Time to fever remission: Two RCTs and one cohort reported this outcome. One of the RCTs reported a shorter time to fever remission with the use of HCQ while the other RCT and a cohort study did not.

Virologic clearance: Three cohort studies and 2 RCTs reported on virologic clearance. Two cohort studies found faster clearance of viral RNA in the HCQ group as compared to the standard of care group at study endpoints. But both the RCTs did not show any benefit in terms of virologic clearance (Table 2).

Safety outcomes: Two cohort studies reported ECG abnormalities and one of them reported a higher occurrence of ECG abnormalities in patients receiving HCQ with or without azithromycin.

However, after adjusting for age, gender, comorbidities and baseline severity, there was no significant increase in odds of ECG abnormality. The other cohort study reported no difference in cardiac arrhythmias.

Meta-analysis:

Meta-analysis of 7 studies showed no significant reduction in mortality with HCQ use [RR 0.98 95% CI 0.66-1.46] (Figure 3). There was no significant difference with regard to clinical deterioration/development of ARDS/need for mechanical ventilation between the HCQ and standard of care [RR 0.90 95% CI 0.47-1.71] (Figure 4). There was no statistically significant difference in virologic clearance between HCQ and placebo in the meta-analysis of 2 RCTs and 3 cohort studies [RR 1.03, 95% CI 0.83-1.28] (Figure 5). The time to fever remission was reported in 2 RCTs and one cohort study; meta-analysis showed reduced time to fever remission in the HCQ arm [mean difference -0.54 days, 95% CI -1.19 to 0.11], which did not attain statistical significance. (Figure 6)

Meta-analysis of two cohort studies suggested an increased risk of ECG abnormalities/cardiac arrhythmias in the HCQ arm as compared to standard of care and this was statistically significant (RR 1.46 [95% CI 1.04-2.06]. (Figure 7)

Critical Appraisal:

We included all clinical studies in humans in which HCQ- or CQ-arm was compared with no HCQ- or CQ-arm. We found significant heterogeneity in the inclusion criteria of the studies in which patients ranged from asymptomatic to severe and critically ill COVID-19. The other causes of heterogeneity were the dosage of HCQ, the use of other supportive care interventions including corticosteroids, antiviral drugs, tocilizumab, and IVIG. The stage of

disease at which the drug was administered and host factors such as age, comorbid conditions were also different between the various studies. Similarly, virologic clearance was checked at various time points from day 6 to day 28. There was a significant risk of bias due to the study design being non randomized in 12 of the 15 included studies. The RCTs were not blinded and fraught with a risk of assessment bias. The reason for giving HCQ/CQ in some patients and not giving in others was not explicitly mentioned in any of the cohort studies. The Cochrane risk of bias tool was used to critically appraise the RCTs and Newcastle Ottawa Scale to assess the risk of bias in cohort studies and the risk is summarized in Figure 2 and Table 4.

Quality of Evidence: The evidence was judged to be of very low quality for the outcomes mortality, clinical deterioration/ARDS/need for mechanical ventilation, virologic clearance (cohort studies), time to fever resolution (cohort studies) and ECG abnormalities. For the outcomes virologic cure (RCTs) and time to fever remission (RCTs) it was judged to be low quality (Table 5).

Discussion

Due to the sheer magnitude of the COVID-19 pandemic and lack of effective therapy, there is a race to find therapies that would improve the clinical outcomes of the patients. Amongst the various medications tried, HCQ has received maximum attention, partly due to the media coverage. A few initial in-vitro studies as well as a proof of concept study by Guatret *et al.* had shown some benefit [15]. Subsequently, many institutional protocols in countries like China, France, US and India[2] mandated the use of HCQ in the management of all patients with COVID-19. This has led to several observational studies being reported in rapid succession,

which were of poor methodologic quality and most did not report outcomes of clinical interest uniformly. There were 3 RCTs but neither of them reported outcomes in terms of mortality, need for mechanical ventilation or ECG abnormalities. The initial observational studies and RCTs had many limitations such as small sample size, heterogenous patient population, variable endpoints, variable dosing of the drug, and no control for confounders.

Serious adverse drug reactions with the use of CQ and HCQ though uncommon have been reported. These include cardiac toxicity in the form of cardiomyopathy and prolonged QTc interval,[27] and hemolysis in patients with underlying G6PD deficiency. Moreover, their therapeutic index is narrow.[28] The NIH panel has recommended against using high-dose chloroquine (600 mg twice daily for 10 days) and a combination of hydroxychloroquine plus azithromycin because of the potential for toxicities.[29] The most recent and largest study which reported a higher mortality was subsequently retracted due to multiple reasons chiefly lack of access to data for independent review held by a private company.[30] The investigators of a multicenter trial, the RECOVERY trial, being conducted in the UK have announced negative results but the full report is still to be published.

Our results are at odds with those of a recent meta-analysis from France which has shown that HCQ results in significant improvements in various clinical parameters including mortality .[31]. However, this meta-analysis did not use the standard methodology for a meta-analysis and did not do a proper risk of bias assessment for the included studies. They also included a study in their meta-analysis which has now been retracted. The quality of evidence was also not graded. At this time, it is important to present credible evidence due to recent scientific controversy, political discourse, and heightened public anxiety.

Conclusion

There is very low quality evidence to suggest that either chloroquine or hydroxychloroquine neither improves mortality or clinical course nor does it hasten virologic clearance in the treatment of COVID-19.

Implications for research

Since the COVID-19 pandemic is ongoing, and >7.1 million patients have been infected worldwide, there is an urgent need to generate robust evidence regarding the efficacy and safety of CQ and HCQ in COVID-19. Randomized controlled studies of adequate sample size with sound methodology are needed to provide definite answers.

Funding: No funding received

Conflicts of interest: None declared

References

1. Coronavirus Update (Live): 7,132,732 Cases and 406,959 Deaths from COVID-19 Virus Pandemic - Worldometer [Internet]. [cited 2020 Jun 8]. Available from: https://www.worldometers.info/coronavirus/?utm_campaign=homeAdUOA?Si,
2. RevisedNationalClinicalManagementGuidelineforCOVID1931032020.pdf [Internet]. [cited 2020 May 29]. Available from: <https://www.mohfw.gov.in/pdf/RevisedNationalClinicalManagementGuidelineforCOVID1931032020.pdf>
3. CDC. Coronavirus Disease 2019 (COVID-19) [Internet]. Centers for Disease Control and Prevention. 2020 [cited 2020 Apr 28]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html>
4. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011 Oct 18;343:d5928.
5. Ottawa Hospital Research Institute [Internet]. [cited 2020 Jun 11]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
6. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008 Apr 26;336(7650):924–6.
7. Borba MGS, Val F de A, Sampaio VS, Ara& MA, Alexandre U, Melo GC, et al. Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study). *medRxiv*. 2020 Apr 16;2020.04.07.20056424.
8. Chen X, Zhang Y, Zhu B, Zeng J, Hong W, He X, et al. Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in Guangzhou, China: a retrospective cohort study. *medRxiv*. 2020 Apr 14;2020.04.09.20058941.
9. Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. *The Lancet* [Internet]. 2020 May 22 [cited 2020 May 23];0(0). Available from: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)31180-6/abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/abstract)
10. Kim MS, Jang S-W, Park Y-K, Kim B, Hwang T-H, Kang SH, et al. Treatment Response to Hydroxychloroquine, Lopinavir/Ritonavir, and Antibiotics for Moderate COVID 19: A First Report on the Pharmacological Outcomes from South Korea. *medRxiv*. 2020 May 18;2020.05.13.20094193.

11. Auld S, Caridi-Scheible M, Blum JM, Robichaux CJ, Kraft CS, Jacob JT, et al. ICU and ventilator mortality among critically ill adults with COVID-19. medRxiv. 2020 Apr 26;2020.04.23.20076737.
12. Yu B, Wang DW, Li C. Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19. medRxiv. 2020 May 1;2020.04.27.20073379.
13. CHEN Jun LD, CHEN Jun LD. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ Med Sci. 2020 Mar 6;49(1):0–0.
14. Feng Z, Li J, Yao S, Yu Q, Zhou W, Mao X, et al. The Use of Adjuvant Therapy in Preventing Progression to Severe Pneumonia in Patients with Coronavirus Disease 2019: A Multicenter Data Analysis. medRxiv. 2020 Apr 10;2020.04.08.20057539.
15. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Mar 20;105949.
16. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020 May 7;0(0):null.
17. Mallat J, Hamed F, Balkis M, Mohamed MA, Mooty M, Malik A, et al. Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study. medRxiv. 2020 May 2;2020.04.27.20082180.
18. Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin JW, Sutton SS, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv. 2020 Apr 23;2020.04.16.20065920.
19. Mahévas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. 2020 May 14;369:m1844.
20. Huang M, Li M, Xiao F, Liang J, Pang P, Tang T, et al. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. medRxiv. 2020 May 4;2020.04.26.20081059.
21. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA [Internet]. 2020 May 11 [cited 2020 May 29]; Available from: <https://jamanetwork.com/journals/jama/fullarticle/2766117>
22. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with

mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. *BMJ*. 2020 14;369:m1849.

23. Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. *medRxiv*. 2020 Apr 10;2020.03.22.20040758.
24. Ip A, Berry DA, Hansen E, Goy AH, Pecora AL, Sinclair BA, et al. Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients - An Observational Study. *medRxiv*. 2020 May 25;2020.05.21.20109207.
25. Singh S, Khan A, Chowdhry M, Chatterjee A. Outcomes of Hydroxychloroquine Treatment Among Hospitalized COVID-19 Patients in the United States- Real-World Evidence From a Federated Electronic Medical Record Network. *medRxiv*. 2020 May 19;2020.05.12.20099028.
26. Novales FJM de, Ramírez-Olivencia G, Estébanez M, Dios B de, Herrero MD, Mata T, et al. Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study. 2020 May 5 [cited 2020 Jun 13]; Available from: <https://www.preprints.org/manuscript/202005.0057/v1>
27. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. *JAMA*. 2020 May 11;
28. Touret F, de Lamballerie X. Of chloroquine and COVID-19. *Antiviral Res*. 2020 May 1;177:104762.
29. Antiviral Therapy | Coronavirus Disease COVID-19 [Internet]. COVID-19 Treatment Guidelines. [cited 2020 May 30]. Available from: <https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/>
30. Mehra MR, Ruschitzka F, Patel AN. Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. *The Lancet* [Internet]. 2020 Jun 5 [cited 2020 Jun 8];0(0). Available from: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)31324-6/abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31324-6/abstract)
31. Million M, Gautret P, Colson P, Roussel Y, Dubourg G, Chabriere E, et al. Clinical Efficacy of Chloroquine derivatives in COVID-19 Infection: Comparative meta-analysis between the Big data and the real world. *New Microbes New Infect*. 2020 Jun 6;100709.

Table 1: Summary Results of the included cohort studies with mortality as outcome									
S. No.	Author	Type of study	Total Patients (n) Age median (range, years) Co-morbidity	Controls (no HCQ) (n)	Severity of illness	Intervention (HCQ); number of patients, Dose, duration	Concomitant medicines	Outcome	Overall benefit
1	Bo Yu et al.	Retrospective Cohort	568 patients Median age 68 years (Range 57-76)	520	Critically ill COVID-19 patients with severe ARDS with PaO ₂ /FiO ₂ <300 on mechanical ventilation	n=48 HCQ 200 mg BD x 7-10 days	received antivirals and supportive care including IVIg, antibiotics and interferons	Mortality 18.8% (9/48) in HCQ group and 45.8% (238/520) in non-HCQ group (p<0.001)	Yes
2	Geleris et al.	Prospective Cohort	1376 Patients with COVID-19 who were hospitalized	565	not intubated for at least 24 hours after starting of HCQ	n=811 HCQ 600 mg on day 1 followed by 400 mg for 4 days;	Azithromycin 500 mg on day 1 followed by 250 mg for 4 days	Respiratory failure needing intubation or death in 252/811 (31%) of HCQ vs 84/565 (14.8%) of non HCQ group (HR 1.04, 95% CI 0.82 to 1.32)*	No
3	Ip et al.	Retrospective cohort	hospitalized COVID-19 n=2512	598	37% had O ₂ saturation <94%	N=1914 HCQ 800 mg on day 1, and 400 mg on day 2-5	77% received azithromycin	Mortality 432/1914 (22.5%) in HCQ arm and 115/598 (19.2%) in non HCQ arm. Propensity-score adjusted hazard ratios, any use of hydroxychloroquine during the hospitalization (HR, 0.99; 95% CI, 0.80-1.22). Arrhythmias 5% in HCQ and 4% in non HCQ arm	No
4	Magagnoli et al,	Retrospective cohort	368 Hospitalized patients	158	136/368 (36.9%) had O ₂ saturation <94%	n=210 HCQ alone, n=97 HCQ+AZ n=113	Standard of care	Mortality in HC, HC+AZ, and no HC groups were 27.8%, 22.1%, 11.4%, respectively. Risk of death higher in HCQ group (HR 2.61; 95% CI, 1.10 to 6.17; P=0.03) but not in HCQ+AZ (HR 1.14; 95% CI 0.56—2.32; p=0.72) Need for ventilation similar in HCQ vs no HCQ	Higher deaths in HCQ group
5	Mahevas et al	Retrospective Cohort	181 Adults, median age 60	97	oxygen requirement	n=84 HCQ 600	Standard of care	20.2% in HCQ group transferred to the ICU or died within 7 days vs	No

			years (IQR 52-68 years); comorbidities lesser in HCQ group		>2L/min	mg/day in first 48 hours of hospitalization		22.1% in the no-HCQ group (RR 0.91, 95% CI 0.47–1.80); 27.4% in HCQ and in non HCQ group 24.1%, respectively, developed ARDS within 7 days (RR 1.14, 95% CI 0.65–2.00)	
6	Membri llo et al.	Prospective cohort	n=168 Hospitalized Age: 18-85 years	43	All patients irrespective of severity	N=123 HCQ Loading dose of 800 mg followed by 400 mg per day of HCQ	Standard of care which included antivirals, immunomodulation including steroids/tocilizumab	Mortality 27/123 (22%) in the HCQ arm vs. 21/43 (48.8%) in the standard of care arm [p=0.002]	Yes
7	Rosenberg et al.	Retrospective cohort	n=1438 median age 63 years, Comorbidities in 60%, commonest hypertension	221	All hospitalized patients, severity not mentioned	HCQ alone or with azithromycin n=1006 HCQ+AZ n=735	Standard of care	Mortality HCQ alone 54/271 (19.9%), vs. HCQ+AZ 189/735 (25.7%) vs. 243/1006 in HCQ vs. 28/211 (12.7%). Overall no difference in mortality for HCQ+AZ (HR, 1.35 [95% CI, 0.76-2.40]), HCQ alone (HR, 1.08 [95% CI, 0.63-1.85]). In regression models of abnormal ECG findings, no significant differences between the groups receiving neither drug vs. HCQ+AZ and HCQ alone	No
8	Singh et al.	Retrospective cohort	n=1125 (N=910 for propensity matched analysis); Mean age 61.45 years	N=2247; (N=910 for propensity matched analysis)	Severity not mentioned	HCQ dose and duration not mentioned; 799 received azithromycin	controls received standard of care/Azithromycin/corticosteroids and no other antivirals or biologics	30 day mortality 104/910 (11.8%) in HCQ vs 109/910 (11.9%) in Standard of care arm (RR 0.95; 95% CI 0.74,1.23) (Propensity score matched sample) Mech. ventilation 46/910 in HCQ vs 57/910 in standard of care	No

*This study evaluated death or intubation as a composite outcome.

CQ: chloroquine; HCQ: hydroxychloroquine; IVIg: intravenous immunoglobulin; Az: azithromycin

Table 2: Summary Results of the included cohort studies with virologic clearance as the outcome									
S. No.	Author	Type of study	Patients (n) Age median (range) years Co-morbidity	Controls (no HCQ) (n)	Severity of illness	Intervention Number, dose	Concomitant medicines	Outcome	Overall benefit
1	Gautret et al	Cohort study with controls from other hospital	42 Hospitalized patients aged >12 years with SARS-CoV-2 positive	16	All stages of COVID	N=26 HCQ 200 mgTDSx10 days	Azithromycin	Virologic clearance at day 6 was 14/20 in the HCQ group vs 2/16 in the non HCQ group	Yes
2	Jihad Mallat et al	Retrospective cohort study	34 Adult patients, 10 had comorbidities, all of them survived	13	6 required oxygen, none required high flow oxygen or ICU care	n=21 HCQ 400 mg BD first day followed by 400 mg OD x 10 days	Standard of care	On day 14, 47.8% (14/23) patients tested negative in the HCQ group compared to 90.9% (10/11) patients who did not receive HCQ (p=0.016)	No
3	Huang et al.	Prospective cohort	233 adult patients with COVID-19 with median age 43 (33-55) years	176	Critical cases excluded	n=197 Chloroquine 500 mg OD (low dose) or BD (high dose)	Standard of care	By day 10, 91.4% of CQ and 57% of non CQ had negative swab and day 14 95.9% of CQ vs 79.6% non CQ had negative swab	Yes

Table 3: Summary Results of the 3 RCTs on HCQ in COVID-19

S. No.	Author	Type of study	Patients (n) Age Co-morbidity	Controls (no HCQ) (n)	Severity of illness	Intervention Number, dose	Concomitant medicines	Outcome	Overall benefit
1	Chen Jun et al.	RCT	30 treatment Naive COVID-19 patients	15	Not available	N=15 HCQ 500 mg/d x 5 days	NA	On day 7, throat swab was negative in 13 (86.7%) cases in the HCQ group and 14 (93.3%) cases in the control group ($P > 0.05$). Median time to fever remission HCQ group was 1 (0-2) vs control group 1 (0-3). Radiological progression was shown on CT images in 5 cases (33.3%) of the HCQ group and 7 cases (46.7%) of the control group	No
2	Wei Tang et al.	RCT	N=150 Adult hospitalized patients positive for SARS CoV-2	75	All patients	n=75 HCQ 1200 mg/d x 3 days followed by 800 mg x 2-3 weeks	Standard of care	28-day negative conversion rate was not different between HCQ and control group (85.4% versus 81.3%, $P=0.34$)	No
3	Chen et al.	RCT	N=62 Adult patients	31	Mild COVID-19	n=31 HCQ 400 mg/day	Standard of care	Compared with the controls [3.2 (1.3) days], the body temperature recovery time was significantly shortened with HCQ [2.2 (0.4) days] CT chest improved on day 6 in HCQ group (80.6%, 25 of 31) compared with the control group (54.8%, 17 of 31)	Yes

Table 4: Newcastle-Ottawa Risk of bias assessment for cohort studies								
	Study ID	Representativeness of exposed cohort	Selection of the non-exposed cohort	Ascertainment of exposure	Demonstration that outcome of interest was not present at start of study	Comparability of cohorts on the basis of the design or analysis controlled for confounders	Assessment of outcome	Was follow-up long enough for outcomes to occur
S. No.	Auld et al.	Truly representative	Drawn from same cohort	Secure record	Yes (Mortality)	Not comparable in terms of baseline characteristics, comorbidities	Record linkage (Death)	Follow up duration not mentioned
1	Bo Yu et al.	Truly representative	Drawn from same cohort	Secure record	Yes (Death)	Comparable in terms of age, gender, comorbidities and baseline severity	Record linkage (death)	Yes
2	Feng et al.	Truly representative	Drawn from same cohort	Secure record	Yes (Development of severe pneumonia)	No explicit mention of differences in baseline characteristics	No description	Yes
3	Gautret et al	Truly representative	Drawn from different cohort	Secure record	Yes (Viral clearance)	Not explicit mention of comorbidities or baseline severity	Record linkage	No (6 days)
4	Geleris et al.	Truly representative	Drawn from same cohort	Secure record	Yes (intubation or death)	Not comparable in terms of comorbidities or co-interventions	Record linkage	Yes
5	Ip et al.	Truly representative	Drawn from same cohort	Secure record	Yes (Mortality) arrhythmias (not specifically looked at)	Not comparable in terms of comorbidities and severity of illness at baseline	Record linkage (mortality) self reporting (arrhythmias)	No
6	Jihad Mallat	Truly representative	Drawn from same cohort	Secure record	Yes (viral clearance)	Not comparable in terms of comorbidities	Record linkage	No (day 14)
7	Kim et al	Truly representative	Drawn from same cohort	Secure record	Yes (Fever resolution)	Not comparable in terms of baseline characteristics and	Self reporting	Yes

							comorbidities		
8	Magagnoli et al,	Only male patients	Drawn from same cohort	Secure record	Yes (Death/mechanical ventilation)		Not comparable in terms of comorbidities, co-interventions or baseline severity	Record linkage	Yes
9	Mahevas et al	Truly representative	Drawn from same cohort	Secure record	Yes (ICU transfer, ARDS development/death)		Not comparable in terms of co-morbidities/baseline severity	ICU transfer/ARDS-self report	Death: Record linkage
10	Membrillo et al	Truly representative	Drawn from same cohort	Secure record	Yes; Death		Not compable in terms of co-morbidities or baseline characteristics	Record linkage (Death)	Yes
11	Huang et al.	Truly representative; excluded critical patients	Drawn from same cohort	Secure record	Yes (Viral clearance)		Comparable in terms of comorbidities/baseline severity	Record linkage	No (day 14)
12	Rosenberg et al.	Truly representative	Drawn from same cohort	Secure record	Yes (In hospital mortality)	ECG abnormalities (Not specifically looked at start of study)	Not comparable in terms of comorbidities, baseline severity	Record linkage for death; ECG abnormalities-self report	Yes
13	Singh et al.	Truly representative	Drawn from same cohort	Secure record	Yes; 30 day mortality, mechanical ventilation		Not comparable in terms of comorbidities	Record linkage-death; Mechanical ventilation-self report	Yes (30 days)

Table 5: Hydroxychloroquine compared to placebo for COVID-19

Patient or population: COVID-19 Intervention: Hydroxychloroquine Comparison: Standard of care					
Outcomes	No of participants (studies) Follow up	Certainty of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with placebo	Risk difference with Hydroxychloroquine
Death	6904 (8 observational studies)	⊕○○○ VERY LOW	RR 0.98 (0.66 to 1.46)	214 per 1,000	4 fewer per 1,000 (73 fewer to 98 more)
Worsening of disease, Need for ventilation or development of ARDS	3857 (6 observational studies)	⊕○○○ VERY LOW	RR 0.90 (0.47 to 1.71)	110 per 1,000	11 fewer per 1,000 (58 fewer to 78 more)
Virologic clearance - RCTs	180 (2 RCTs)	⊕⊕○○ LOW	RR 1.02 (0.90 to 1.15)	833 per 1,000	17 more per 1,000 (83 fewer to 125 more)
Virologic clearance - Cohort study	443 (3 observational studies)	⊕○○○ VERY LOW	RR 1.21 (0.64 to 2.29)	749 per 1,000	157 more per 1,000 (270 fewer to 966 more)
Time to fever remission - RCTs	92 (2 RCTs)	⊕⊕○○ LOW	-	The mean time to fever remission - RCTs was 0	MD 0.51 lower (1.49 lower to 0.47 higher)
Time to fever remission - Cohort	62 (1 observational study)	⊕○○○ VERY LOW	-	The mean time to fever remission - Cohort was 0	MD 0.6 lower (1.37 lower to 0.17 higher)
ECG abnormalities	3534 (2 observational studies)	⊕○○○ VERY LOW	RR 1.46 (1.04 to 2.06)		

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; MD: Mean difference

GRADE Working Group grades of evidence

High certainty: **We are very confident that the true effect lies close to that of the estimate of the effect**

Moderate certainty: **We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different**

Low certainty: **Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect**

Very low certainty: **We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect**

Figure legends

Figure 1: PRISMA flow diagram for study selection

Figure 2: Risk of bias assessment for included RCTs

Figure 3: Effect of HCQ on mortality in patients with COVID-19

Figure 4: Effect of HCQ on clinical deterioration/need for mechanical ventilation in patients with COVID-19


Figure 5: Effect of HCQ on virological clearance in patients with COVID-19

Figure 6: Effect of HCQ on time to fever remission in patients with COVID-19

Figure 7: Effect of HCQ on ECG abnormalities in patients with COVID-19



Figure 1: PRISMA Flow Diagram for study selection



Chen Jun 2020

Wei Tang 2020

Zhaowei Chen 2020

Random sequence generation (selection bias)

Allocation concealment (selection bias)

Blinding of participants and personnel (performance bias)

Blinding of outcome assessment (detection bias)

Incomplete outcome data (attrition bias)

Selective reporting (reporting bias)

?

?

-

?

?

?

+

?

-

-

+

+

+

+

-

-

+

+

Category	2020		2021		Weight	2022		Total Score
	Score	Rank	Score	Rank		Score	Rank	
Category 1	85	10	80	15	1.0	82.5	12.5	
Category 2	75	20	70	25	1.0	72.5	22.5	
Category 3	90	5	85	10	1.0	87.5	7.5	
Category 4	65	30	60	35	1.0	62.5	32.5	
Category 5	80	15	75	20	1.0	77.5	17.5	
Category 6	70	25	65	30	1.0	67.5	27.5	
Category 7	85	10	80	15	1.0	82.5	12.5	
Category 8	75	20	70	25	1.0	72.5	22.5	
Category 9	90	5	85	10	1.0	87.5	7.5	
Category 10	65	30	60	35	1.0	62.5	32.5	
Category 11	80	15	75	20	1.0	77.5	17.5	
Category 12	70	25	65	30	1.0	67.5	27.5	
Category 13	85	10	80	15	1.0	82.5	12.5	
Category 14	75	20	70	25	1.0	72.5	22.5	
Category 15	90	5	85	10	1.0	87.5	7.5	
Category 16	65	30	60	35	1.0	62.5	32.5	
Category 17	80	15	75	20	1.0	77.5	17.5	
Category 18	70	25	65	30	1.0	67.5	27.5	
Category 19	85	10	80	15	1.0	82.5	12.5	
Category 20	75	20	70	25	1.0	72.5	22.5	
Category 21	90	5	85	10	1.0	87.5	7.5	
Category 22	65	30	60	35	1.0	62.5	32.5	
Category 23	80	15	75	20	1.0	77.5	17.5	
Category 24	70	25	65	30	1.0	67.5	27.5	
Category 25	85	10	80	15	1.0	82.5	12.5	
Category 26	75	20	70	25	1.0	72.5	22.5	
Category 27	90	5	85	10	1.0	87.5	7.5	
Category 28	65	30	60	35	1.0	62.5	32.5	
Category 29	80	15	75	20	1.0	77.5	17.5	
Category 30	70	25	65	30	1.0	67.5	27.5	
Category 31	85	10	80	15	1.0	82.5	12.5	
Category 32	75	20	70	25	1.0	72.5	22.5	
Category 33	90	5	85	10	1.0	87.5	7.5	
Category 34	65	30	60	35	1.0	62.5	32.5	
Category 35	80	15	75	20	1.0	77.5	17.5	
Category 36	70	25	65	30	1.0	67.5	27.5	
Category 37	85	10	80	15	1.0	82.5	12.5	
Category 38	75	20	70	25	1.0	72.5	22.5	
Category 39	90	5	85	10	1.0	87.5	7.5	
Category 40	65	30	60	35	1.0	62.5	32.5	
Category 41	80	15	75	20	1.0	77.5	17.5	
Category 42	70	25	65	30	1.0	67.5	27.5	
Category 43	85	10	80	15	1.0	82.5	12.5	
Category 44	75	20	70	25	1.0	72.5	22.5	
Category 45	90	5	85	10	1.0	87.5	7.5	
Category 46	65	30	60	35	1.0	62.5	32.5	
Category 47	80	15	75	20	1.0	77.5	17.5	
Category 48	70	25	65	30	1.0	67.5	27.5	
Category 49	85	10	80	15	1.0	82.5	12.5	
Category 50	75	20	70	25	1.0	72.5	22.5	
Category 51	90	5	85	10	1.0	87.5	7.5	
Category 52	65	30	60	35	1.0	62.5	32.5	
Category 53	80	15	75	20	1.0	77.5	17.5	
Category 54	70	25	65	30	1.0	67.5	27.5	
Category 55	85	10	80	15	1.0	82.5	12.5	
Category 56	75	20	70	25	1.0	72.5	22.5	
Category 57	90	5	85	10	1.0	87.5	7.5	
Category 58	65	30	60	35	1.0	62.5	32.5	
Category 59	80	15	75	20	1.0	77.5	17.5	
Category 60	70	25	65	30	1.0	67.5	27.5	
Category 61	85	10	80	15	1.0	82.5	12.5	
Category 62	75	20	70	25	1.0	72.5	22.5	
Category 63	90	5	85	10	1.0	87.5	7.5	
Category 64	65	30	60	35	1.0	62.5	32.5	
Category 65	80	15	75	20	1.0	77.5	17.5	
Category 66	70	25	65	30	1.0	67.5	27.5	
Category 67	85	10	80	15	1.0	82.5	12.5	
Category 68	75	20	70	25	1.0	72.5	22.5	
Category 69	90	5	85	10	1.0	87.5	7.5	
Category 70	65	30	60	35	1.0	62.5	32.5	
Category 71	80	15	75	20	1.0	77.5	17.5	
Category 72	70	25	65	30	1.0	67.5	27.5	
Category 73	85	10	80	15	1.0	82.5	12.5	
Category 74	75	20	70	25	1.0	72.5	22.5	
Category 75	90	5	85	10	1.0	87.5	7.5	
Category 76	65	30	60	35	1.0	62.5	32.5	
Category 77	80	15	75	20	1.0	77.5	17.5	
Category 78	70	25	65	30	1.0	67.5	27.5	
Category 79	85	10	80	15	1.0	82.5	12.5	
Category 80	75	20	70	25	1.0	72.5	22.5	
Category 81	90	5	85	10	1.0	87.5	7.5	
Category 82	65	30	60	35	1.0	62.5	32.5	
Category 83	80	15	75	20	1.0	77.5	17.5	
Category 84	70	25	65	30	1.0	67.5	27.5	
Category 85	85	10	80	15	1.0	82.5	12.5	
Category 86	75	20	70	25	1.0	72.5	22.5	
Category 87	90	5	85	10	1.0	87.5	7.5	
Category 88	65	30	60	35	1.0	62.5	32.5	
Category 89	80	15	75	20	1.0	77.5	17.5	
Category 90	70	25	65	30	1.0	67.5	27.5	
Category 91	85	10	80	15	1.0	82.5	12.5	
Category 92	75	20	70	25	1.0	72.5	22.5	
Category 93	90	5	85	10	1.0	87.5	7.5	
Category 94	65	30	60	35	1.0	62.5	32.5	
Category 95	80	15	75	20	1.0	77.5	17.5	
Category 96	70	25	65	30	1.0	67.5	27.5	
Category 97	85	10	80	15	1.0	82.5	12.5	
Category 98	75	20	70	25	1.0	72.5	22.5	
Category 99	90	5	85	10	1.0	87.5	7.5	
Category 100	65	30	60	35	1.0	62.5	32.5	
Category 101	80	15	75	20	1.0	77.5	17.5	
Category 102	70	25	65	30	1.0	67.5	27.5	
Category 103	85	10	80	15	1.0	82.5	12.5	
Category 104	75	20	70	25	1.0	72.5	22.5	
Category 105	90	5	85	10	1.0	87.5	7.5	
Category 106	65	30	60	35	1.0	62.5	32.5	
Category 107	80	15	75	20	1.0	77.5	17.5	
Category 108	70	25	65	30	1.0	67.5	27.5	
Category 109	85	10	80	15	1.0	82.5	12.5	
Category 110	75	20	70	25	1.0	72.5	22.5	
Category 111	90	5	85	10	1.0	87.5	7.5	
Category 112	65	30	60	35	1.0	62.5	32.5	
Category 113	80	15	75	20	1.0	77.5	17.5	
Category 114	70	25	65	30	1.0	67.5	27.5	
Category 115	85	10	80	15	1.0	82.5	12.5	
Category 116	75	20	70	25	1.0	72.5	22.5	
Category 117	90	5	85	10	1.0	87.5	7.5	
Category 118	65	30	60	35	1.0	62.5	32.5	
Category 119	80	15	75	20	1.0	77.5	17.5	
Category 120	70	25	65	30	1.0	67.5	27.5	
Category 121	85	10	80	15	1.0	82.5	12.5	
Category 122	75	20	70	25	1.0	72.5	22.5	
Category 123	90	5	85	10	1.0	87.5	7.5	
Category 124	65	30	60	35	1.0	62.5	32.5	
Category 125	80	15	75	20	1.0	77.5	17.5	
Category 126	70	25	65	30	1.0	67.5	27.5	
Category 127	85	10	80	15	1.0	82.5	12.5	
Category 128	75	20	70	25	1.0	72.5	22.5	
Category 129	90	5	85	10	1.0	87.5	7.5	
Category 130	65	30	60	35	1.0	62.5	32.5	
Category 131	80	15	75	20	1.0	77.5	17.5	
Category 132	70	25	65	30	1.0	67.5	27.5	
Category 133	85	10	80	15	1.0	82.5	12.5	
Category 134	75	20	70	25	1.0	72.5	22.5	
Category 135	90	5	85	10	1.0	87.5	7.5	
Category 136	65	30	60	35	1.0	62.5	32.5	
Category 137	80	15	75	20	1.0	77.5	17.5	
Category 138	70	25	65	30	1.0	67.5	27.5	
Category 139	85	10	80	15	1.0	82.5	12.5	
Category 140	75	20	70	25	1.0	72.5	22.5	
Category 141	90	5	85	10	1.0	87.5	7.5	
Category 142	65	30	60	35	1.0	62.5	32.5	
Category 143	80	15	75	20	1.0	77.5	17.5	
Category 144	70	25	65	30	1.0	67.5	27.5	
Category 145	85	10	80	15	1.0	82.5	12.5	
Category 146	75	20	70	25	1.0	72.5	22.5	
Category 147	90	5	85	10	1.0	87.5	7.5	
Category 148	65	30	60	35	1.0	62.5	32.5	
Category 149	80	15	75	20	1.0	77.5	17.5	
Category 150	70	25	65	30	1.0	67.5	27.5	
Category 151	85	10	80	15	1.0	82.5	12.5	
Category 152	75	20	70	25	1.0	72.5	22.5	
Category 153	90	5	85	10	1.0	87.5	7.5	
Category 154	65	30	60	35	1.0	62.5	32.5	
Category 155	80	15	75	20	1.0	77.5	17.5	
Category 156	70	25	65	30	1.0	67.5	27.5	
Category 157	85	10	80	15	1.0	82.5	12.5	
Category 158	75	20	70	25	1.0	72.5	22.5	
Category 159	90	5	85	10	1.0	87.5	7.5	
Category 160	65	30	60	35	1.0	62.5	32.5	
Category 161	80	15	75	20	1.0	77.5	17.5	
Category 162	70	25	65	30	1.0	67.5	27.5	
Category 163	85	10	80	15	1.0	82.5	12.5	
Category 164	75	20	70	25	1.0	72.5	22.5	
Category 165	90	5	85	10	1.0	87.5	7.5	
Category 166	65	30	60	35	1.0	62.5	32.5	
Category 167	80	15	75	20	1.0	77.5	17.5	
Category 168	70	25	65	30	1.0	67.5	27.5	
Category 169	85	10	80	15	1.0	82.5	12.5	
Category 170	75	20	70	25	1.0	72.5	22.5	
Category 171	90	5	85	10	1.0	87.5	7.5	
Category 172	65	30	60	35	1.0	62.5	32.5	
Category 173	80	15	75	20	1.0	77.5	17.5	
Category 174	70	25	65	30	1.0	67.5	27.5	
Category 175	85	10	80	15	1.0	82.5	12.5	
Category 176	75	20	70	25	1.0	72.5	22.5	
Category 177	90	5	85	10	1.0	87.5	7.5	
Category 178	65	30	60	35	1.0	62.5	32.5	
Category 179	80	15	75	20	1.0	77.5	17.5	
Category 180	70	25	65	30	1.0	67.5	27.5	
Category 181	85	10	80	15	1.0	82.5	12.5	
Category 182	75	20	70	25	1.0	72.5	22.5	
Category 183	90	5	85	10	1.0	87.5	7.5	

	2023		2022		2021		2020	
Category	Q1	Q2	Q1	Q2	Q1	Q2	Q1	Q2
Category 1	100	120	110	130	120	140	130	150
Category 2	200	250	220	270	240	290	260	310
Category 3	300	350	320	370	340	390	360	410
Category 4	400	450	420	470	440	490	460	510
Category 5	500	550	520	570	540	590	560	610
Category 6	600	650	620	670	640	690	660	710
Category 7	700	750	720	770	740	790	760	810
Category 8	800	850	820	870	840	890	860	910
Category 9	900	950	920	970	940	990	960	1010
Category 10	1000	1050	1020	1070	1040	1090	1060	1110

Category	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10
Category 1	100	120	140	160	180	200	220	240	260	280
Category 2	200	250	300	350	400	450	500	550	600	650
Category 3	300	350	400	450	500	550	600	650	700	750
Category 4	400	450	500	550	600	650	700	750	800	850
Category 5	500	550	600	650	700	750	800	850	900	950
Category 6	600	650	700	750	800	850	900	950	1000	1050
Category 7	700	750	800	850	900	950	1000	1050	1100	1150
Category 8	800	850	900	950	1000	1050	1100	1150	1200	1250
Category 9	900	950	1000	1050	1100	1150	1200	1250	1300	1350
Category 10	1000	1050	1100	1150	1200	1250	1300	1350	1400	1450



	EBC1		Control		Weight		Risk Factor		Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	OR, Odds Ratio	95% CI	OR, Odds Ratio	95% CI	
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1	10	100	5	100	50%	0.5	0.2, 1.2	0.5	0.2, 1.2	
2. EBC1 EBC1	15	100	10	100	50%	1.5	0.8, 2.8	1.5	0.8, 2.8	
Statistical pool (CI)		200		200	100%	1.0	0.5, 2.0	1.0	0.5, 2.0	
Heterogeneity:										
Chi-square										
I-squared										
Test for overall effect										
Test for subgroup effect										
EBC1 EBC1										
1. EBC1 EBC1										

[illegible]

